Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]
, 2012 T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor +5 more
core +1 more source
POS0206 DESIGN AND CHARACTERISATION OF A THERAPEUTIC BISPECIFIC TANDEM scFv-Fc FUSION PROTEIN WITH ANTI-TNF AND SYNOVIUM-TARGETING SPECIFICITY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS [PDF]
, 2021 S. Pagani +2 more
openalex +1 more source
Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion
Advanced Science, EarlyView.The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li +10 more
wiley +1 more source
Prompting Fab Yeast Surface Display Efficiency by ER Retention and Molecular Chaperon Co-expression. [PDF]
, 2019 For antibody discovery and engineering, yeast surface display (YSD) of antigen-binding fragments (Fabs) and coupled fluorescence activated cell sorting (FACS) provide intact paratopic conformations and quantitative analysis at the monoclonal level, and ...
Ge, Xin +7 more
core
Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells [PDF]
, 2012 Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required
Breckpot, Karine +10 more
core +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
Advanced Science, EarlyView.This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
Directed evolution of human scFvs in DT40 cells [PDF]
Protein Engineering Design and Selection, 2015 Cells that constitutively diversify their immunoglobulin genes can be used for selection of novel antibodies and for refining existing affinities and specificities. Here, we report an adaptation of the chicken DT40 system wherein its capacity for somatic hypermutation is harnessed to evolve human antibodies expressed as single-chain variable fragments (
Lim, Alfred W.Y. +3 more
openaire +2 more sources
Seed-produced anti-globulin VHH-Fc antibodies retrieve globulin precursors in the insoluble fraction and modulate the Arabidopsis thaliana seed subcellular morphology [PDF]
, 2020 Key message Nanobody-heavy chain (VHH-Fc) antibody formats have the potential to immunomodulate even highly accumulating proteins and provide a valuable tool to experimentally modulate the subcellular distribution of seed storage proteins.
Altmann, Friedrich +7 more
core +2 more sources
Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy
Advanced Science, EarlyView.Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee +11 more
wiley +1 more source
A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth
Brazilian Journal of Medical and Biological Research, 2012 Doxorubicin (DOX) was conjugated to a single-chain variable fragment (scFv) against human midkine (MK), and the conjugate (scFv-DOX) was used to target the chemotherapeutic agent to a mouse solid tumor model in which the tumor cells expressed high levels
Shuli Zhao +4 more
doaj +2 more sources